Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 265.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 10.00 (3.846%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 265.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Renalytix hails trial results; Kingswood buys JFP

Thu, 01st Dec 2022 21:42

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Renalytix PLC - London-based diagnostics company focused on kidney health - Notes the results of primary care use of KidneyIntelX in early-stage chronic kidney disease. Reports a 10% improvement in the HBA1c levels in high-risk patients in first six months. Says that 57% of high-risk patients had action taken within 3-months, compared to 35% for low-risk patients. "The impacts of KidneyIntelX early risk assessment, at 90 days and 180 days, are very encouraging as we can now state that we have observed early intervention in the highest risk patients can result in positive clinical outcomes, before kidney disease advances to a critical point. This prospective study in a real-world health care system setting demonstrates that risk-informed care in the earliest stages of chronic kidney disease is not just a vision, it's a reality," Chief Medical Officer Michael Donovan comments.

----------

Fox Marble Holdings PLC - marble quarrying - Says it was awarded EUR383,177 in damages plus GBP454,584 in costs by in the London Court of International Arbitration from its proceedings against a customer based in India. Says no issues remain to be awarded. The amounts awarded bear an interest rate of 8% per year, it says.

----------

Panther Metals PLC - Canada-focused mineral exploration company - Receives the findings of the follow-up geochemical soil sampling programme 1 in the Barker area of the Manitou Lakes project in Ontario, Canada. Identifies a 300-meter strike extent of linear anomalous and high-grade gold in soils at the Barker prospect area. "These results from the latest round of soil geochemical sampling at Manitou Lakes have almost doubled the strike extent of anomalous gold to 700m at the exciting Barker area prospect in the east of the project area," Chief Executive Darren Hazelwood says.

----------

Kingswood Holdings Ltd - London-based wealth and investment management - Buys Cheshire-based financial advisory firm JFP Holdings Ltd. It is the holding company of JFP Financial Services Ltd. Pays a total cash consideration of up to GBP12.4 million, payable over a two-year period. "The acquisition of JFP Holdings will expand our geographical footprint into the Northwest region and an affluent South Manchester area. JFP Holdings are a high-quality business that has operated with its affiliate Josolyne & Co, a leading chartered accountancy practice, for many years," CEO David Lawrence comments.

----------

Synergia Energy Ltd - Perth-based developer of natural gas assets in India, Indonesia and the UK, formerly called Oilex Ltd - Says that gas production from its C-77H well at the Cambay was around average of 270,000 cubic feet per day in November. Says oil production from the field averaged 23 barrels of oil per day for the month.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Appoints Maija Hollmen as chief scientific officer. "Hollmen is the world-leading expert on Clever-1 biology and Clever-1-expressing tumour-associated macrophages," Chief Medical Officer Marie-Louise Fjallskog says. "Her support is essential to bexmarilimab's development. Faron is pleased to have her on board in the chief scientific officer role to bring her knowledge of the target molecule and develop it further."

----------

Kropz PLC - African phosphate developer - Says that it agreed to a ZAR121.5 million, or USD7.1 million, bridge loan facility to meet its immediate cash requirements at Elandsfontein. Reports that ZAR242.5 million remains available for drawdown over the term of the ZAR550 million equity facility.

----------

Riverstone Credit Opportunities Income PLC - energy infrastructure and energy-transition credit investor - Realised its investment in Hoover CS with a USD1.6 million gross profit. Also reports an upsized investment in a new sustainability-linked first-lien term loan for Hoover. "Hoover CS has a demonstrated track record of helping its customers across multiple end markets improve environmental performance and the circularity of their supply chains, and we are pleased to partner with them on their next phase of growth. This investment is in-line with our stated yield target and focus on sustainability-linked loans. It also means that RCOI is now almost fully invested," Managing Director Danny Flannery comments.

----------

US Solar Fund PLC - owns and operates solar power assets in North America - Reports changes to key personnel at its investment manager New Energy Solar Manager Pty Ltd. Explains that these changes come amid strategic reviews. Says Liam Thomas will continue to lead the strategic review. Says that Adam Haughton will be leaving NESM in December to pursue an alternative career opportunity. "The board remains fully committed to the strategic review process and is entirely focused on delivering a successful outcome that maximises value for all our shareholders as soon as practically possible. The board would like to wish both Liam and Adam well in their new endeavours and thank them for their commitment to USF since its IPO," Chair Gill Nott says.

----------

Gensource Potash Corp - fertilizer development company based in Saskatchewan, Canada - Plans to raise gross proceeds of CAD6.0 million, or GBP3.6 million, in a non-brokered private placement. The offering will consist of up to 20.0 million units of the company at a price of CAD0.15 per unit. Further, it plans to offer up to 15.0 million common shares at a price of CAD0.20 per flow through share. Intends to use the net proceeds from the sale of the units to advance the Tugaske project.

----------

Atome Energy PLC - Leeds, England-based producer and marketer of green hydrogen and ammonia - Says that it achieved "significant" progress at the Villeta project in Paraguay. Says that its green hydrogen and ammonia Villeta project expanded to a world-scale 120 megawatt capacity capable of producing up to 100,000 metric tonnes of ammonia per year. "We are grateful for the confidence that ANDE [the Paraguayan National Power Company] is showing in Atome by increasing our power supply to 120MW, enabling Paraguay to become the leader on the continent in the fast-growing green hydrogen economy. In parallel, we are announcing that, after a competitive tender process including some of the leading engineers in the field, we have appointed as [front-end engineering design] contractor, a very strong consortium of engineering and industrial companies with a track record of delivering ground-breaking energy projects across Latin America and the world, combined with unparalleled expertise in the ammonia sector," CEO Olivier Mussat comments.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
7 Dec 2023 11:01

Faron publishes cancer immunotherapy study findings

(Sharecast News) - Faron Pharmaceuticals announced the publication of the comprehensive findings from the groundbreaking phase one and two 'MATINS' trial of bexmarilimab on Thursday - its humanised monoclonal anti-CLEVER-1 antibody aimed at transforming the landscape of anticancer immunotherapies.

Read more
6 Nov 2023 11:03

IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial

Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibody bexmarilimab in patients with aggressive myeloid leukemias. Says it has selected hypomethylating agents-refractory or relapsed myelodysplastic syndromes (MDS) as the initial indication, based on US Food & Drug Administration guidance. Phase 1 data "demonstrated that optimal target engagement can be achieved with three milligrams per kilogram dosing" with both three and six milligram cohorts showing the "highest immune activation", while the drug produced a 50% remission rate in doublet dose cohorts.

Read more
6 Nov 2023 10:31

Faron reveals details of next stage of bexmarilimab study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that, following guidance from the US Food and Drug Administration (FDA), the initial indication for phase two advancement in the study investigating bexmarilimab in combination with standard of care, would focus on hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndromes (MDS).

Read more
30 Oct 2023 15:56

TRADING UPDATES: Bezant optimistic after Hope & Gorob estimate

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
11 Oct 2023 14:53

Faron Pharmaceuticals upbeat on latest data in blood cancer trials

(Sharecast News) - Faron Pharmaceuticals announced encouraging updated data from its ongoing phase one and two 'BEXMAB' study into relapsed or refractory (r/r) acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) treatments on Wednesday.

Read more
11 Oct 2023 14:01

IN BRIEF: Faron Pharmaceuticals' Bexmarilimab shows 50% remission rate

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Says Bexmarilimab study shows 50% remission rate for patients with in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Says eight of eleven patients were complete responders or complete responders with incomplete blood recovery. Adds Bexmarilimab continues to be well-tolerated at all tested dose levels, as no dose-limiting toxicity has been observed.

Read more
21 Sep 2023 14:45

Faron Pharmaceuticals names interim chief medical officer

(Sharecast News) - Cancer immunotherapy-focussed biopharmaceutical firm Faron Pharmaceuticals named Dr Birge Berns as its interim chief medical officer on Thursday, with the transition becoming effective on 22 September, with Dr Berns operating from the UK.

Read more
21 Sep 2023 12:12

TRADING UPDATES: Faron appoints Birge Berns as interim medical officer

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
15 Sep 2023 15:46

UK shareholder meetings calendar - next 7 days

Monday 18 September 
Baillie Gifford US Growth Trust PLCAGM
Inteliqo LtdAGM
LendInvest PLCAGM
Rosslyn Data Technologies PLCGM re fundraise
Tuesday 19 September 
Africa Opportunity Fund LtdAGM
Aston Martin Lagonda Global Holdings PLCGM re supply arrangement with Lucid Group Inc
Augmentum Fintech PLCAGM
Beacon Rise Holdings PLCAGM
Begbies Traynor Group PLCAGM
Chill Brands Group PLCAGM
DP Aircraft I LtdAGM
Great Southern Copper PLCAGM
Manolete Partners PLCAGM
Moonpig Group PLCAGM
Oxford Instruments PLCAGM
ProCook Group PLCAGM
SRT Marine Systems PLCAGM
Unicorn Mineral Resources PLCAGM
Wednesday 20 September 
Accsys Technologies PLCAGM
Frasers Group PLCAGM
Games Workshop Group PLCAGM
Hidong Estate PLCAGM
IG Group Holdings PLCAGM
Ilika PLCAGM
Nippon Active Value Fund PLCGM re assets rollover
Quiz PLCAGM
Seed Innovations LtdAGM
STS Global Income & Growth Trust PLCAGM
Thursday 21 September 
Ascent Resources PLCGM re audited annual accounts
Intercede Group PLCAGM
Kore Potash PLCGM re capital raise
Liontrust Asset Management PLCAGM
Mercia Asset Management PLCAGM
Molecular Energies PLCAGM
Oberon Investments Group PLCAGM
Pelatro PLCGM re AIM cancellation
Sosandar PLCAGM
Thruvision Group PLCAGM
Trakm8 Holdings PLCAGM
Van Elle Holdings PLCAGM
Friday 22 September 
Argos Resources LtdGM re members voluntary liquidation
B&M European Value Retail SAGM re appointing Lasry as director
Faron Pharmaceuticals LtdEGM re election of new board members
Stranger Holdings PLCAGM
SysGroup PLCAGM
TI Fluid Systems PLCGM re waiver resolution
Odyssean Investment Trust PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
29 Aug 2023 10:23

AIM WINNERS & LOSERS: Pelatro plummets on delisting plans

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
29 Aug 2023 10:15

Faron shares surge on FDA drug designation; loss widens on costs

(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday said its interim loss widened on higher costs but saw shares soar after it gained a US Food & Drug Administration orphan drug designation for Bexmarilimab.

Read more
22 Aug 2023 15:46

UK earnings, trading statements calendar - next 7 days

Wednesday 23 August 
Angling Direct PLCTrading Statement
Costain Group PLCHalf Year Results
Thursday 24 August 
Benchmark Holdings PLCQ3 Results
CRH PLCHalf Year Results
Harbour Energy PLCHalf Year Results
Hays PLCFull Year Results
Hunting PLCHalf Year Results
James Cropper PLCHalf Year Results
Macfarlane Group PLCHalf Year Results
Princess Private Equity Holding LtdHalf Year Results
Redcentric PLCFull Year Results
South32 LtdFull Year Results
Tribal Group PLCHalf Year Results
Friday 25 August 
no events scheduled 
Monday 28 August 
no events scheduled 
Tuesday 29 August 
Amaroq Minerals LtdHalf Year Results
Bunzl PLCHalf Year Results
Dalata Hotel Group PLCHalf Year Results
Faron Pharmaceuticals LtdHalf Year Results
PureTech Health PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
19 Jul 2023 10:27

Faron Pharmaceuticals sees positive data from phase 1 BEXMAB trial

(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said data from its phase 1 BEXMAB study has shown positive data.

Read more
29 Jun 2023 18:55

TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.